CVM News and Press, Cel-Sci Corporation From 12/28/22

Cel-Sci press release ( NYSE: CVM ): FY net operating loss of ~$36.1M for the twelve months ended September 30, 2022, of which ~$11.4M was non-cash expense including stock-based employee compensation and ~$3.8M in depreciation and amortization expense while cash spent was $18.2M. ...

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments. Clinical and Corporate Developments: CEL-SCI’s main focus throughout fiscal year 2022 has been to complete a...

Summary CEL-SCI's Multikine is a patented cocktail of cytokines, which recently completed an ~10 year pivotal trial preparatory for a long awaited BLA filing. During its anguished and extended history, CEL-SCI's shareholders have paid a heavy price. As it drifts down <$3.00, CEL-...

5 patients had no tumor left following a 3-week treatment of CEL-SCI’s investigational drug Multikine Images clearly show tumors in the patients’ oral cavity prior to treatment with Multikine and the disappearance of these tumors before any subsequent sta...

Summary CEL-SCI demonstrated significant clinical benefits for head & neck cancer patients. In the lower-risk group, there was a 14.1% absolute survival improvement. One of the treatment arms (higher risk) shows the control group doing better than the test arm, which is a ...

CEL-SCI ( NYSE: CVM ) reported data from a phase 3 trial of neoadjuvant multikine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck at the European Society for Medical Oncology (EMSO) annual Congress in Paris, France. ...

Poster presentations by Dr. Philip Lavin, a biostatistician for 80 FDA approvals/clearances, and Dr. József Tímár, Professor and Director of the Central Pathology Laboratory at Semmelweis University View the posters here: LINK CEL-SCI C...

Clinical-stage biotech CEL-SCI Corporation ( NYSE: CVM ) announced Wednesday that the company would respond to the FDA with a “major follow-up package” after the regulator raised questions and comments on its cancer immunotherapy Multikine. CVM has conducted ...

The “Proposed Indication” for Multikine that will be submitted to the FDA in a license application will be limited by certain eligibility criteria to patients who would be deemed by NCCN Guidelines as having a lower risk for tumor recurrence. The Standard of Care for l...

Cel-Sci press release ( NYSE: CVM ): Q3 GAAP EPS of -$0.66. Net cash used during the nine months ended June 30, 2022 was $13.3M. This represents a decrease of $0.7 million compared to the nine months ended June 30, 2021. For further details see: Cel-Sci ...